基础研究

肠道微生物网络在高草酸诱导大鼠肾损伤中的保护作用

  • 王演 ,
  • 潘铁军 ,
  • 刘振宇 ,
  • 孙进波 ,
  • 周宇 ,
  • 李超圣 ,
  • 高磊
展开
  • 中国人民解放军中部战区总医院泌尿外科 (武汉 430000 )

收稿日期: 2023-07-12

  网络出版日期: 2024-07-09

基金资助

国家自然科学基金项目(81502210);中部战区总医院育英计划面上项目(ZZY202211)

Protective role of intestinal microbial network in hyperoxaluria⁃induced kidney impairment in rats

  • Yan WANG ,
  • Tiejun PAN ,
  • Zhenyu LIU ,
  • Jinbo SUN ,
  • Yu ZHOU ,
  • Chaosheng LI ,
  • Lei. GAO
Expand
  • Department of Urology,the General Hospital of Central Theater Command of Chinese People′s Liberation Army,Wuhan 430000,China

Received date: 2023-07-12

  Online published: 2024-07-09

摘要

目的 探讨肠道菌群移植(FMT)对高草酸饮食大鼠草酸代谢的影响及肾脏保护作用。 方法 将24只雄性SD大鼠随机分为SC组、SC + FMT组、OD + PBS组及OD + FMT组。其中,SC组为对照组,正常大鼠饲料喂养;OD + PBS组及OD + FMT组采用5%草酸含量的饲料喂养。第14天起,OD + PBS组、OD + FMT组及SC + FMT组分别给予PBS溶液及豚鼠粪便滤液灌胃,连续7 d。收集各组大鼠的24 h尿液、粪便及静脉血清,测定肠道菌群及血清尿液生化指标;取大鼠肾脏进行实时定量PCR及免疫组化检测肾素、ACE及OPN的表达情况。 结果 肠道菌群移植影响了大鼠的肠道菌群,SC + FMT组大鼠的肠道菌群偏离了SC组大鼠的肠道菌群并与豚鼠肠道菌群的相似度提高;与OD + PBS组比较,OD + FMT组的尿草酸、尿素、尿酸、肌酐、血尿素氮/肌酐以及血尿酸明显降低。此外,经FMT治疗后,与OD + PBS组相比,OD + FMT组上调的肾素mRNA表达的被降低,下调的OPN mRNA表达得到了恢复;免疫组化得到了类似的结果。 结论 肠道菌群移植激活了大鼠肠道中以Muribaculaceae等草酸降解菌为代表的微生物网络。高草酸诱导的肾脏损伤因微生物网络对草酸的降解而恢复,肠道菌群移植对大鼠肾脏具有保护作用。

本文引用格式

王演 , 潘铁军 , 刘振宇 , 孙进波 , 周宇 , 李超圣 , 高磊 . 肠道微生物网络在高草酸诱导大鼠肾损伤中的保护作用[J]. 实用医学杂志, 2024 , 40(13) : 1771 -1777 . DOI: 10.3969/j.issn.1006-5725.2024.13.002

Abstract

Objective To explore the effects of fecal microbiota transplantation (FMT) on oxalate metabolism and renal protection in rats fed a high oxalate diet. Methods Twenty-four male SD rats were randomly divided into four groups: SC, SC + FMT, OD + PBS and OD + FMT. The SC group was set as the control group and was fed standard rat chow. The OD + PBS group and OD + FMT group were fed a diet containing 5% oxalate. Starting from day 14, the OD + PBS group, OD + FMT group and SC + FMT group received intragastric administration of PBS solution or filtered faecal microbiota solution from guinea pigs for 7 consecutive days. The 24-hour urine, feces, and venous serum of the rats were collected from the rats of all groups to determine the gut microbiota and biochemical markers. Real-time quantitative PCR and immunohistochemistry were conducted on the rat kidneys to detect the expression of renin, ACE, and OPN. Results The fecal microbiota transplantation altered the gut microbiota of rats. The gut microbiota of the SC + FMT group deviated from that of the SC group and showed increased similarity to that of the guinea pigs. Compared to the OD + PBS group, the OD + FMT group exhibited significant reductions in the urinary oxalate, urinary urea, uric acid, urinary creatinine, serum urea nitrogen/creatinine, and serum uric acid. Furthermore, after FMT treatment, the OD + FMT group exhibited reduced upregulation of renin mRNA expression and restored downregulation of OPN mRNA expression compared to the OD + PBS group; similar results were obtained from immunohistochemistry. Conclusion Fecal microbiome trans-plantation activated the microbial network in the rat gut, particularly the oxalate-degrading bacteria represented by Muribaculaceae. The kidney injury induced by high oxalate was partially restored by the microbiota network's degradation of oxalate, indicating the protective effect of fecal microbiota transplantation on the rat kidneys.

参考文献

1 吴志良. 不同手术方式治疗男性复杂性肾结石的疗效和对患者性功能影响的比较[J]. 实用医学杂志, 2018,34(20):3449-3453. doi:10.3969/j.issn.1006-5725.2018.20.030
2 XU L, ADAMS-HUET B, POINDEXTER J R, et al. Temporal Changes in Kidney Stone Composition and in Risk Factors Predisposing to Stone Formation[J]. J Urol, 2017,197(6):1465-1471. doi:10.1016/j.juro.2017.01.057
3 LIESKE J C, PE?A DE LA VEGA L S, SLEZAK J M, et al. Renal stone epidemiology in Rochester, Minnesota: An update[J]. Kidney Int, 2006,69(4):760-764. doi:10.1038/sj.ki.5000150
4 CIL O, CHU T, LEE S, et al. Small-molecule inhibitor of intestinal anion exchanger SLC26A3 for treatment of hyperoxaluria and nephrolithiasis[J]. JCI Insight, 2022,7(13):e153359. doi:10.1172/jci.insight.153359
5 CANALES B K, HATCH M. Kidney stone incidence and metabolic urinary changes after modern bariatric surgery: review of clinical studies, experimental models, and prevention strategies[J]. Surg Obes Relat Dis, 2014,10(4):734-742. doi:10.1016/j.soard.2014.03.026
6 HOLMES R P, KNIGHT J, ASSIMOS D G. Lowering urinary oxalate excretion to decrease calcium oxalate stone disease[J]. Urolithiasis, 2016,44(1):27-32. doi:10.1007/s00240-015-0839-4
7 MITCHELL T, KUMAR P, REDDY T, et al. Dietary oxalate and kidney stone formation[J]. Am J Physiol Renal Physiol, 2019,316(3): F409-F413. doi:10.1152/ajprenal.00373.2018
8 TURRONI S, BENDAZZOLI C, DIPALO S C F, et al. Oxalate-Degrading Activity inBifidobacterium animalis subsp.lactis: Impact of Acidic Conditions on the Transcriptional Levels of the Oxalyl Coenzyme A (CoA) Decarboxylase and Formyl-CoA Transferase Genes[J]. Appl Environ Microbiol, 2010,76(16):5609-5620. doi:10.1128/aem.00844-10
9 MOGNA L, PANE M, NICOLA S, et al. Screening of Different Probiotic Strains for Their In Vitro Ability to Metabolise Oxalates: Any Prospective Use in Humans? [J]. J Clin Gastroenterol, 2014,48(Supp1):S91-S95. doi:10.1097/mcg.0000000000000228
10 KAUFMAN D W, KELLY J P, CURHAN G C, et al. Oxalobacter formigenes May Reduce the Risk of Calcium Oxalate Kidney Stones[J]. J Am Soc Nephrol, 2008,19(6):1197-1203. doi:10.1681/asn.2007101058
11 STERN J M, MOAZAMI S, QIU Y, et al. Evidence for a distinct gut microbiome in kidney stone formers compared to non-stone formers[J]. Urolithiasis, 2016,44(5):399-407. doi:10.1007/s00240-016-0882-9
12 TICINESI A, MILANI C, GUERRA A, et al. Understanding the gut–kidney axis in nephrolithiasis: an analysis of the gut microbiota composition and functionality of stone formers[J]. Gut, 2018,67(12):2097-2106. doi:10.1136/gutjnl-2017-315734
13 TAVASOLI S, ALEBOUYEH M, NAJI M, et al. Association of intestinal oxalate‐degrading bacteria with recurrent calcium kidney stone formation and hyperoxaluria: a case–control study[J]. BJU Int, 2020,125(1):133-143. doi:10.1111/bju.14840
14 CHEN F, BAO X, LIU S, et al. Gut microbiota affect the formation of calcium oxalate renal calculi caused by high daily tea consumption[J]. Appl Microbiol Biotechnol, 2021,105(2):789-802. doi:10.1007/s00253-020-11086-w
15 GOLDFARB D S, MODERSITZKI F, ASPLIN J R. A Randomized, Controlled Trial of Lactic Acid Bacteria for Idiopathic Hyperoxaluria[J]. Clin J Am Soc Nephrol, 2007,2(4):745-749. doi:10.2215/cjn.00600207
16 HOPPE B, GROOTHOFF J W, HULTON S, et al. Efficacy and safety of Oxalobacter formigenes to reduce urinary oxalate in primary hyperoxaluria[J]. Nephrol Dial Transplant, 2011,26(11):3609-3615. doi:10.1093/ndt/gfr107
17 SIENER R, BADE D J, HESSE A, et al. Dietary hyperoxaluria is not reduced by treatment with lactic acid bacteria[J]. J Transl Med, 2013,11:306. doi:10.1186/1479-5876-11-306
18 HOPPE B, NIAUDET P, SALOMON R, et al. A randomised Phase I/II trial to evaluate the efficacy and safety of orally administered Oxalobacter formigenes to treat primary hyperoxaluria[J]. Pediatr Nephrol, 2017,32(5):781-790. doi:10.1007/s00467-016-3553-8
19 MILLINER D, HOPPE B, GROOTHOFF J. A randomised Phase II/III study to evaluate the efficacy and safety of orally administered Oxalobacter formigenes to treat primary hyperoxaluria[J].Urolithiasis, 2018,46(4):313-323. doi:10.1007/s00240-017-0998-6
20 MILLER A W, OAKESON K F, DALE C, et al. Microbial Community Transplant Results in Increased and Long-Term Oxalate Degradation[J]. Microb Ecol, 2016,72(2):470-478. doi:10.1007/s00248-016-0800-2
21 MILLER A W, DALE C, DEARING M D. The Induction of Oxalate Metabolism In Vivo Is More Effective with Functional Microbial Communities than with Functional Microbial Species[J]. mSystems, 2017,2(5):e00088-17. doi:10.1128/msystems.00088-17
22 SIDHU H, ALLISON M J, CHOW J O M, et al. Rapid reversal of hyperoxaluria in a rat model after probiotic administration of Oxalobacter formigenes[J]. J Urol, 2001,166(4):1487-1491. doi:10.1016/s0022-5347(05)65817-x
23 SALAZAR N, DE LOS REYES-GAVILáN C G. Editorial: Insights into Microbe-Microbe Interactions in Human Microbial Ecosystems: Strategies to Be Competitive[J]. Front Microbiol, 2016,7:1508. doi:10.3389/fmicb.2016.01508
24 GREEN J E, DAVIS J A, BERK M, et al. Efficacy and safety of fecal microbiota transplantation for the treatment of diseases other than Clostridium difficile infection: a systematic review and meta-analysis[J]. Gut Microbes, 2020,12(1):1-25. doi:10.1080/19490976.2020.1854640
25 STERN J M, URBAN-MALDONADO M, USYK M, et al. Fecal transplant modifies urine chemistry risk factors for urinary stone disease[J]. Physiol Rep, 2019,7(4):e14012. doi:10.14814/phy2.14012
26 MILLER A W, CHOY D, PENNISTON K L, et al. Inhibition of urinary stone disease by a multi-species bacterial network ensures healthy oxalate homeostasis[J]. Kidney Int, 2019,96(1):180-188. doi:10.1016/j.kint.2019.02.012
27 张建清, 王庆, 江克华, 等. microRNA在肾结石疾病中的作用机制和研究进展[J]. 实用医学杂志, 2023,39(6):773-777. doi:10.3969/j.issn.1006-5725.2023.06.021
文章导航

/